scholarly journals Bruck Syndrome: A Rare Disorder in New-Born with Fractures and Contractures

2018 ◽  
Vol 37 (3) ◽  
pp. 276-279
Author(s):  
Suraj Dhaubhadel ◽  
Bimala Baniya ◽  
Hema Joshi ◽  
Ram Hari Chapagain ◽  
Krishna Prasad Paudel

Bruck syndrome is a very rare autosomal recessive syndrome consisting of bone fragility and congenital joint contractures. It is considered as a combination of arthrogryposis multiplex congenita and osteogenesis imperfecta, while some consider it as the autosomal recessive variant of osteogenesis imperfecta. According to the genotype, it has been classified into types 1 and 2. To our knowledge, only about 28 patients of this syndrome have been reported so far worldwide with none been reported from Nepal. Here, we present a patient with generalized osteopenia, bilateral femur fracture and congenital joint contractures of distal extremities.

1998 ◽  
Vol 28 (2) ◽  
pp. 117-119 ◽  
Author(s):  
M. F. Blacksin ◽  
Beth A. Pletcher ◽  
Miriam David

2012 ◽  
Vol 33 (10) ◽  
pp. 1444-1449 ◽  
Author(s):  
Maria Trinidad Puig-Hervás ◽  
Samia Temtamy ◽  
Mona Aglan ◽  
Maria Valencia ◽  
Víctor Martínez-Glez ◽  
...  

2008 ◽  
Vol 36 (2) ◽  
pp. 122-126 ◽  
Author(s):  
Denis Viljoen ◽  
Gerry Versfeld ◽  
Peter Beighton

2005 ◽  
Vol 10 (6) ◽  
pp. 641-646 ◽  
Author(s):  
Lipalo Mokete ◽  
Anthony Robertson ◽  
Denis Viljoen ◽  
Peter Beighton

2009 ◽  
Vol 29 (2) ◽  
pp. 159-162 ◽  
Author(s):  
H. Yapicioğlu ◽  
K. Özcan ◽  
Ö Arikan ◽  
M. Satar ◽  
N. Narli ◽  
...  

2021 ◽  
Vol 10 (14) ◽  
pp. 3141
Author(s):  
Hyerin Jung ◽  
Yeri Alice Rim ◽  
Narae Park ◽  
Yoojun Nam ◽  
Ji Hyeon Ju

Osteogenesis imperfecta (OI) is a genetic disease characterized by bone fragility and repeated fractures. The bone fragility associated with OI is caused by a defect in collagen formation due to mutation of COL1A1 or COL1A2. Current strategies for treating OI are not curative. In this study, we generated induced pluripotent stem cells (iPSCs) from OI patient-derived blood cells harboring a mutation in the COL1A1 gene. Osteoblast (OB) differentiated from OI-iPSCs showed abnormally decreased levels of type I collagen and osteogenic differentiation ability. Gene correction of the COL1A1 gene using CRISPR/Cas9 recovered the decreased type I collagen expression in OBs differentiated from OI-iPSCs. The osteogenic potential of OI-iPSCs was also recovered by the gene correction. This study suggests a new possibility of treatment and in vitro disease modeling using patient-derived iPSCs and gene editing with CRISPR/Cas9.


Sign in / Sign up

Export Citation Format

Share Document